BZydus Lifesciences’ New Jersey facility clears USFDA inspection with nil observations
The inspection covered the company’s pharmacovigilance and post-marketing surveillance system and was conducted from September 22 to September 25.
The inspection covered the company’s pharmacovigilance and post-marketing surveillance system and was conducted from September 22 to September 25.
Business Line - Home
This report is indexed by BAGANBAZAR GRAPH with its original publisher named and linked for readers.
Read at original outlet ↗